An Overview of the Meta-analyses of the Hypertension Treatment Trials

Archives of Internal Medicine

Volumn 151, Issue 7, 1991, Pages 1277-1279

  Moser, Marvin ^a   Hebert, Patricia ^a   Hennekens, Charles H ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; META ANALYSIS; NOTE; PREVENTION; PRIORITY JOURNAL; STROKE;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CORONARY DISEASE; FOLLOW-UP STUDIES; HUMAN; HYPERTENSION; INCIDENCE; META-ANALYSIS;

EID: 0025815594     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400070055005     Document Type: Article

References (30)

1. 1. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
2. 2. Kaplan N. Meta-analysis of hypertension treatment trials. Lancet. 1990;335:1093.
3. 3. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Progr Cardiovasc Dis. 1989;29(suppl 1):99-118.
4. 4. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571.
5. 5. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
6. 6. Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1:1261-1267.
7. 7. Veterans Administration Cooperative Study Group on Antihypertensive Agents, II: results of patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1151.
8. 8. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
9. 9. Moser M. Clinical trials and their effect on medical therapy: the Multiple Risk Factor Intervention Trial. Am Heart J. 1984;107:616-618.
10. 10. Hebert PR, Fiebach NH, Eberlein KA, Taylor JO, Hennekens CH. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol. 1988;127:581-590.
11. 11. European Working Party on High Blood Pressure in the Elderly. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly. Lancet. 1985;1:1349-1354.
12. 12. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
13. 13. Moser M. Suppositions and speculations: their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118:1362-1369.
14. 14. Hansson L, Robertson JIS. Is hypertension treated adequately? Drugs. 1987;34(suppl 3):1-6.
15. 15. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA. 1988;259:2113-2122.
16. 16. Perry M. Six-year compliance with a treatment regimen and resultant control of blood pressure in special VA hypertension clinics. J Hypertens. 1986;4(suppl 5):S393-S396
17. 17. Zussman RM. Alternatives to traditional antihypertensive therapy. Hypertension. 1986;8:837-842.
18. 18. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension. 1988;11(suppl 11):II-165-II-20.
19. 19. Freis ED. Critique of the clinical importance of diuretic-induced hypokalemia and elevated cholesterol level. Arch Intern Med. 1989;149:2649-2658.
20. 20. Moser M. Lipid abnormalities and diuretics. Am Fam Phys. 1989;40:21320.
21. 21. Shapiro AP, Benedik TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. N Engl J Med. 1961;265:1028-1033.
22. 22. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
23. 23. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand. 1985;701(suppl):38-52.
24. 24. Eschewege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metabol Res. 1985;15(suppl):41-46.
25. 25. Cullen K, Stenhouse NS, Wearne KL, Welborn TA. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia: 13-case study. J Chronic Dis. 1983;36:371-377.
26. 26. Jarrett RJ. Is insulin atherogenic? Diabetologia. 1989;31:71-75.
27. 27. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
28. 28. Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chronic Dis. 1966;19:227-240.
29. 29. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409-418.
30. 30. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.